From the Journals

Hexavalent hepatitis B vaccination mostly immunogenic 10 years later


 

FROM VACCINE

Immune memory persisted in more than 80% of children aged at least 10 years after two-dose primary and booster vaccination with a hexavalent hepatitis B (HB) vaccine, results of an Italian study show.

The phase 3 open-label, controlled study included 732 healthy Italian children aged 11-13 years who as infants had received a two-dose primary and booster course with either Hexavac (5 mcg hepatitis B surface antigen [HBsAg]) or Infanrix hexa (10 mcg HBsAg) at 3, 5, and 11 months of age; the last dose was received at least 10 years prior to the challenge dose of a monovalent HB vaccine (HBVaxPro, 5 mcg HBsAg).

This digitally colorized transmission electron micrograph reveals the presence of hepatitis B virions. The large round virions are known as Dane particles. CDC/Dr. Erskine Palmer
One month after the challenge dose, 84% (95% confidence interval, 80-87) and 96% (95% CI, 94-98) of children in the Hexavac and Infanrix hexa groups, respectively, had protective concentrations of HB surface antigen antibody of at least 10 mIU/mL, reported Dr. Alessandro Zanetti of Università degli Studi di Milano (Italy) and associates (Vaccine. 2017 Jul 13;35[32]:4034-40).

Although some of the children had HB surface antigen antibody concentrations below the seroprotection threshold, most of them had an anamnestic response when challenged with the dose of HB vaccine, “indicating the presence of specific immune memory,” the investigators said. There was no evidence of active HB disease in any of the children.

Just what the meaning of the lack of immune memory is, defined as the failure to develop an anamnestic response following an HB vaccine challenge, remains to be determined.

Recommended Reading

ACIP approves new hepatitis A vaccine draft recommendations
MDedge Family Medicine
If doctors recommend it, teens are more likely to get HPV vaccine
MDedge Family Medicine
ACIP approves new influenza vaccine recommendations
MDedge Family Medicine
Small study: Patients prefer microneedle flu vaccine
MDedge Family Medicine
English infant quadravalent group B meningococcal vaccine pays off
MDedge Family Medicine
Childhood vaccine trauma decreases adolescent HPV immunization uptake
MDedge Family Medicine
Measles: Why it’s still a threat
MDedge Family Medicine
How to raise HPV vaccine rates: Work together
MDedge Family Medicine
OMV meningococcal vaccine also protected against gonorrhea
MDedge Family Medicine
Vaccination does not eliminate risk for meningococcal disease in eculizumab recipients
MDedge Family Medicine